

Outcome in AlzeCure's rights issue

AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced the outcome of the rights issue with preferential rights for the shareholders (the "Rights Issue") that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters of the Rights Issue will be allocated approximately 20.8 percent of the Rights Issue thus resulting in that AlzeCure obtains SEK 48.5 million before issue costs. Those who have been allocated shares without the support of subscription rights will be notified by contract note alternatively through their nominee.

The subscription period for the Rights Issue ended on March 22, 2022 and the summary shows that 8,654,688 shares, corresponding to approximately 57.3 percent, were subscribed for by the exercise of subscription rights. In addition, the Company received interest from investors of subscribing an additional 324,629 shares without the support of subscription rights, corresponding to approximately 2.1 percent for a total subscription with and without the exercise of subscription rights of 59.4 percent. Consequently underwriters of the Rights Issue will be allocated 20.8 percent of the Rights Issue thus resulting in that AlzeCure obtains SEK 48.5 million before issue costs. Notification of allotment of shares subscribed for without exercising subscription rights will shortly be sent to those who have been allotted shares via contract note. Nominee shareholders receive notification of allotment in accordance with the respective nominee's routines. Allocation of shares subscribed for without the exercise of subscription rights has been carried out in accordance with the principles stated in the prospectus that was published on March 4, 2022.

"Despite an uncertain and turbulent surrounding world, both our current and new shareholders have joined this financing round. The capital injection provides AlzeCure with the necessary funds to carry out the highly interesting clinical phase II study for ACD440 as well as to continue to advance the ongoing Alzheimer projects, all of which have potential of substantial value contribution to our shareholders. We look forward to wholeheartedly devote our aggregate resources to continued progress in our three research platforms", says Martin Jönsson, CEO AlzeCure.

Share capital and number of shares

After the Rights Issue is registered with The Swedish Companies Registration Office the Company's share capital will increase with SEK 303,064.50 to SEK 1,247,207.375. The number of shares will increase with 12,122,580 shares to 49,888,295 shares.

Trading in BTA

Trading in paid subscribed shares ("BTA") will take place on Nasdaq First North Growth Market until the week after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration of the Rights Issue is expected to take place during week 15, 2022.

Advisors

Erik Penser Bank AB is financial advisor and Synch Advokat AB is legal advisor to AlzeCure in connection with the Rights Issue.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se

This information is information that AlzeCure Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-03-24 18:15 CET.

Attachments

Outcome in AlzeCure's rights issue